Covid-19 antiviral study moves to phase 3 testing – Prime Time Zone

3

Medicine was given orally for five days in adult patients with coronavirus; so far, side effects have not been identified

Cadu Rolim / Estadão ContentsIt is estimated that the final studies with the drug will be completed by October

An antiviral medicine against Covid-19 advanced to phase 3 of the tests. Results demonstrated benefits of the compound for the treatment of the disease at mild and moderate levels in outpatients. MSD, an American biopharmaceutical company, and Ridgeback Biotherapeutics, a biotechnology company focused on combating emerging infectious diseases, announced advances in studies of the molnupiravir, an oral antiviral medication that works by preventing the virus from replicating.

The medical director of MSD, Márcia Abadi explains that the drug showed significant efficacy in the initial treatment of the disease in the 300 patients surveyed. “The idea of ​​this study, then, is exactly that, that the patient takes up to the first five days of mild to moderate symptoms and, with that, we prevent him from going to the inflammatory phase, to some worsening phase and to be hospitalized. The primary objective is to assess hospitalizations and death in 29 days. ” The drug was administered orally for five days, twice a day in adult patients with coronavirus. There were no side effects and it ended up being well tolerated by the patients. The estimate is that the final studies will be completed by October, to be subsequently submitted for approval by the Anvisa.

* With information from reporter Daniel Lian